Thioredoxin upregulation by 5-aminolaevulinic acid-based photodynamic therapy in human skin squamous cell carcinoma cell line

Photodermatology Photoimmunology and Photomedicine

Volumn 24, Issue 3, 2008, Pages 142-146

  Kuhara, Tomoe ^a   Watanabe, Daisuke ^a   Akita, Yoichi ^a   Takeo, Tomohiro ^a   Ishida, Natsuko ^a   Nakano, Aki ^a   Yamashita, Noriko ^a   Ohshima, Yuichiro ^a   Kawada, Morihiro ^a   Yanagishita, Takeshi ^a   Tamada, Yasuhiko ^a   Matsumoto, Yoshinari ^a  

^a AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

5 aminolaevulinic acid; Cancer; Photodynamic therapy; Reactive oxygen species (ROS); Thioredoxin

Indexed keywords

AMINOLEVULINIC ACID; CASPASE 3; LIPOCORTIN 5; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROPIDIUM IODIDE; THIOREDOXIN;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL ASSAY; CELL DEATH; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION DOSE; RADIATION EXPOSURE; SKIN CARCINOMA; SQUAMOUS CELL CARCINOMA; UPREGULATION; WESTERN BLOTTING;

AMINOLEVULINIC ACID; ANALYSIS OF VARIANCE; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CASPASE 3; CELL DEATH; CELL LINE, TUMOR; CELL PROLIFERATION; COLLAGEN TYPE XI; HUMANS; LASERS, DYE; MICROSCOPY, FLUORESCENCE; NEOPLASM RECURRENCE, LOCAL; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; RADIATION DOSAGE; THIOREDOXINS; UP-REGULATION;

EID: 43649102205     PISSN: 09054383     EISSN: 16000781     Source Type: Journal    
DOI: 10.1111/j.1600-0781.2008.00354.x     Document Type: Article

References (31)

1. Peng Q, Waroloe T, Berg K, et al. 5-vulinic acid-based photodynamic therapy. Clinical research and future challenges. Cancer 1997; 79: 2282-2308.
2. Fritsch C, Goerz G, Ruzicka T. Photodynamic therapy in dermatology. Arch Dermatol 1998; 134: 207-214.
3. Calzavara-Pinton PG, Venturini M, Sala R. Photodynamic therapy: Update 2006 part1: Photochemistry and photobiology. J Eur Acad Dermatol Venereol 2007; 21: 439-451.
4. Matsumoto Y, Muro Y, Banno S, Ohashi M, Tamada Y. Differential apoptotic pattern induced by photodynamic therapy and cisplatin in human squamous cell carcinoma cell line. Arch Dermatol Res 1996; 289: 52-54.
5. Akita Y, Kozaki K, Nakagawa A, et al. Cyclooxygenase-2 is a possible target of treatment approach in conjunction with photodynamic therapy for various disorders in skin and oral cavity. Br J Dermatol 2004; 151: 472-480.
6. Lahmann P. Methyl aminolaevulinate-photodynamic therapy: A review of clinical trials in the treatment of actinic keratoses and nonmelanoma skin cancer. Brit J Dermatol 2007; 156: 793-801.
7. Laurent TC, Moore EC, Reichard P, et al. Enzymatic synthesis of deoxyribonucleotides. IV. Isolation and characterization of thioredoxin, the hydrogen donor from Escherichia coli B. J Biol Chem 1964; 239: 3436-3444.
8. Tagaya Y, Maeda Y, Mitsui A, et al. ATL-derived factor (ADF), an IL-2 receptor/Tac inducer homologous to thioredoxin; possible involvement of dithiol-reduction in the IL-2 receptor induction. EMBO J 1989; 8: 757-764.
9. Watson WH, Yang X, Choi YE, Jones DP, Kehrer JP. Thioredoxin and its role in toxicology. Toxicol Sci 2004; 78: 3-14.
10. Hirota K, Matsui M, Iwata S, Nishiyama A, Mori K, Yodoi J. AP-1 transcriptional activity is regulated by a direct association between thioredoxin and Ref-1. Proc Natl Acad Sci USA 1997; 94: 3633-3638.
11. Ueno M, Masutani H, Arai RJ, et al. Thioredoxin dependent redox regulation of p53-mediated p21 activation. J Biol Chem 1999; 274: 35809-35815.
12. Abate C, Patel L, Rauscher FJ, Curran T. Redox regulation of fos and jun DNA-binding activity in vitro. Sciences 1990; 249: 1157-1161.
13. Saitoh M, Nishitoh H, Fujii M, et al. Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J 1998; 17: 2596-2606.
14. Grogan TM, Fenoglio-Prieser C, Zeheb R, et al. Thioredoxin, a puntative oncogene product, is overexpressed in gastric carcinoma and associated with increased proliferation and increased cell survival. Hum Pathol 2000; 31: 475-481.
15. Mustacich D, Wagner A, Williams R, et al. Increased skin carcinogenesis in a keratinocyte directed thioredoxin-1 transgenic mouse. Carcinogenesis 2004; 25: 1983-1989.
16. Nakaseko H, Kobayashi M, Akita Y, Tamada Y, Matsumoto Y. Histological changes and involvement of apoptosis after photodynamic therapy for actinic keratosis. Br J Dermatol 2003; 148: 122-127.
17. Haller JC, Cairnduff F, Slack G, et al. Routine double treatments of superficial basal call carcinomas using aminolevulinic acid-based photodynamic therapy. Br J Dermatol 2000; 143: 1270-1275.
18. Morton CA, Whitehurst C, McColl JH, Moore JV, Mackie RM. Photodynamic therapy for large or multiple patches of Bowen disease and basal cell carcinoma. Arch Dermatol 2001; 137: 319-324.
19. Shieh S, Dee AS, Cheney RT, Frawley NP, Zeitouni NC, Oseroff AR. Photodynamic therapy for the treatment of extramammary Paget's disease. Br J Dermatol 2002; 146: 1000-1005.
20. Fisher AM, Murphree AL, Gomer CJ. Clinical and preclinical photodynamic therapy. Lasers Surg Med 1995; 17: 2-31.
21. Dougherty TJ, Gomer CJ, Henderson BW, et al. Photodynamic therapy. J Natl Cancer Inst 1998; 90: 889-905.
22. Svaasand LO, Wyss P, Wyss MT, et al. Dosimetry model for photodynamic therapy with topically administered photosensitizers. Lasers Surg Med 1996; 18: 139-149.
23. Goldberg LH, Kimyai-Asadi A. Diffuse epidermal and periadnexal squamous cell carcinoma in situ: A report of 13 patients. J Am Acad Dermatol 2005; 53: 623-627.
24. Sachi Y, Hirota K, Masutani H, et al. Induction of ADF/TRX by oxidative stress in keratinocytes and lymphoid cells. Immunol Lett 1995; 44: 189-193.
25. Funasaka Y, Ichihashi M. The effect of ultraviolet B induced adult cell leukemia-derived factor/thioredoxin (ADF/TRXD) on survival and growth of human melanocytes. Pigment Cell Res 1997; 10: 68-73.
26. Didier C, Kerblat I, Drouet C, Favier A, Beani JC, Richard MJ. Induction of thioredoxin by ultraviolet-A radiation prevents oxidative-mediated cell death in human skin fibroblasts. Free Rad Biol 2001; 31: 585-598.
27. Didier C, Pouget JP, Favier A, Beani JC, Richard MJ. Modulation of exogenous and endogenous levels of thioredoxin in human skin fibroblasts prevents DNA damaging effect of ultraviolet A radiation. Free Rad Biol Med 2001; 30: 537-546.
28. Chae HZ, Kim HJ, Kang SW, Rhee SG. Characterization of three isoforms of mammalian peroxiredoxin that reduce peroxides in the presence of thioredoxin. Diabetes Res Clin Pract 1999; 45: 101-112.
29. Takasawa R, Tanuma S. Sustained release of Smac/DIABLO from mitochondria commits to undergo UVB-induced apoptosis. Apoptosis 2003; 8: 291-299.
30. Babilas P, Schacht V, Liebsch G, et al. Effects of fractionation and different fluence rates on photodynamic therapy with 5-aminolaevulinic acid in vivo. Brit J Cancer 2003; 88: 1462-1469.
31. Bisland SK, Lilge L, Lin A, Rusnov R, Wilson BC. Metronomic photodynamic therapy as a new paradigm for photodynamic therapy: Rationale and preclinical evaluation of technical feasibility for treating malignant brain tumors. Photochem Photobiol 2004; 80: 22-30.